| Literature DB >> 35410379 |
Genevieve H L Roberts1, Raghavendran Partha2, Brooke Rhead2, Spencer C Knight2, Danny S Park2, Marie V Coignet2, Miao Zhang2, Nathan Berkowitz2, David A Turrisini2, Michael Gaddis2, Shannon R McCurdy2, Milos Pavlovic1, Luong Ruiz2, Chodon Sass1, Asher K Haug Baltzell1, Harendra Guturu2, Ahna R Girshick2, Catherine A Ball2, Eurie L Hong2, Kristin A Rand3.
Abstract
Multiple COVID-19 genome-wide association studies (GWASs) have identified reproducible genetic associations indicating that there is a genetic component to susceptibility and severity risk. To complement these studies, we collected deep coronavirus disease 2019 (COVID-19) phenotype data from a survey of 736,723 AncestryDNA research participants. With these data, we defined eight phenotypes related to COVID-19 outcomes: four phenotypes that align with previously studied COVID-19 definitions and four 'expanded' phenotypes that focus on susceptibility given exposure, mild clinical manifestations and an aggregate score of symptom severity. We performed a replication analysis of 12 previously reported COVID-19 genetic associations with all eight phenotypes in a trans-ancestry meta-analysis of AncestryDNA research participants. In this analysis, we show distinct patterns of association at the 12 loci with the eight outcomes that we assessed. We also performed a genome-wide discovery analysis of all eight phenotypes, which did not yield new genome-wide significant loci but did suggest that three of the four 'expanded' COVID-19 phenotypes have enhanced power to capture protective genetic associations relative to the previously studied phenotypes. Thus, we conclude that continued large-scale ascertainment of deep COVID-19 phenotype data would likely represent a boon for COVID-19 therapeutic target identification.Entities:
Mesh:
Year: 2022 PMID: 35410379 DOI: 10.1038/s41588-022-01042-x
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330